Tempus AI (NASDAQ: TEM) experienced a sharp rally on August 19, driven by external clinical trial results that sparked a technical short squeeze. The stock broke decisively above its major moving averages, signaling that bulls have regained control across multiple timeframes.
Following Wednesday's surge, Tempus AI shares are trading nearly 50% above their July low. The catalyst came not from the company itself, but from landmark Phase 3 trial results announced by Merck and Moderna for their personalized mRNA melanoma vaccine, which is being developed in combination with Keytruda.
The significance for Tempus AI lies in its pending acquisition of Personalis, a company that provides sequencing technology crucial to Moderna's vaccine pipeline. Tempus AI agreed to acquire Personalis for approximately $1.5 billion last month. Initially, the acquisition weighed on TEM shares due to concerns about dilution and costs. However, the trial success has shifted the narrative, validating the strategic value of the sequencing infrastructure Tempus AI is set to inherit.
On August 19, Tempus AI's relative strength index climbed into the mid-60s, indicating intense buying pressure that could sustain upward momentum in the near term. The stock's advance was also supported by fundamental improvements. Just weeks earlier, the company reported its first quarterly net profit of $5.6 million, alongside a 22% year-over-year increase in revenue to $382.5 million. Management subsequently raised its full-year revenue guidance to approximately $1.6 billion.
Additional confidence came from a study published in Nature Medicine validating Tempus AI's PRISM2 pathology AI model, as well as a new oncology companion diagnostics partnership with CellCarta. Combined with elevated short interest of about 20% heading into August 19, the stage was set for a classic short squeeze.
From a technical perspective, Wednesday's high-volume breakout cleared major overhead resistance at $58, converting that level into immediate support. With the 50-day and 200-day moving averages turning sharply upward, the broader technical structure favors continued upside toward the $65 mark, where profit-taking may temporarily cool momentum.
However, sustaining these multi-week highs will depend on smooth regulatory clearance for the Personalis transaction and flawless execution as revenue synergies materialize into late 2026. If the broader market remains risk-on, Tempus AI's swing to profitability and expanding diagnostic footprint position it well to consolidate above $60 before testing its next leg higher.
According to The Wall Street Journal, the consensus rating on Tempus AI stands at Overweight, with price targets as high as $100 per share. For more context on the broader market reaction, see the Dow's climb and Moderna's surge.
This article is for informational purposes only and does not constitute financial advice.
